Can renal fibrosis be reversed?

被引:43
作者
Eddy, AA
机构
[1] Univ Washington, Div Nephrol, Seattle, WA 98105 USA
[2] Childrens Hosp & Reg Med Ctr, Seattle, WA 98105 USA
关键词
fibrosis; regression; myofibroblast; regeneration; matrix;
D O I
10.1007/s00467-005-1995-5
中图分类号
R72 [儿科学];
学科分类号
100202 ;
摘要
New therapeutic approaches are needed to address the current epidemic of chronic kidney disease. Beyond delaying the inevitable onset of end-stage kidney disease the ultimate dream of clinical therapy is disease regression. Degradation of the interstitial matrix proteins is potentially feasible, especially before the interstitial "scar" becomes highly organized. Currently the specific matrix-degrading proteases that perform this function in vivo have not been clearly identified although several candidates have been suggested. Reversing renal fibrosis will also mandate removal of interstitial myofibroblasts that are the major source of the fibrosis-associated interstitial matrix proteins. However, the greater therapeutic challenge pertains to the current inability to regenerate intact functional nephrons in a site where they have been destroyed. In chronic tubulointerstitial damage that typifies all progressive kidney diseases, it is not interstitial matrix accumulation per se that leads to renal functional decline but rather its destructive effects on neighboring cells. In particular, loss of peritubular capillaries and tubules are the morphological features that underlie declining renal function. Recent advances in several basic scientific fields of investigation such as matrix biology, developmental biology, angiogenesis, and stem cell biology have identified new candidate therapeutic targets. A powerful new molecular tool-box is at our disposal that can be used to begin to translate recent discoveries into the clinical research arena with the goal of reversing renal fibrosis in a functionally meaningful way.
引用
收藏
页码:1369 / 1375
页数:7
相关论文
共 58 条
  • [51] WIGGINS R, 1993, LAB INVEST, V68, P557
  • [52] Yang B, 2001, J AM SOC NEPHROL, V12, P275, DOI 10.1681/ASN.V122275
  • [53] Disruption of tissue-type plasminogen activator gene in mice reduces renal interstitial fibrosis in obstructive nephropathy
    Yang, JW
    Shultz, RW
    Mars, WM
    Wegner, RE
    Li, YJ
    Dai, CS
    Nejak, K
    Liu, YH
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 2002, 110 (10) : 1525 - 1538
  • [54] Reduction in connective tissue growth factor by antisense treatment ameliorates renal tubulointerstitial fibrosis
    Yokoi, H
    Mukoyama, M
    Nagae, T
    Mori, K
    Suganami, T
    Sawai, K
    Yoshioka, T
    Koshikawa, M
    Nishida, T
    Takigawa, M
    Sugawara, A
    Nakao, K
    [J]. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2004, 15 (06): : 1430 - 1440
  • [55] Zatz R, 2002, J HYPERTENS, V20, pS37
  • [56] BMP-7 counteracts TGF-β1-induced epithelial-to-mesenchymal transition and reverses chronic renal injury
    Zeisberg, M
    Hanai, J
    Sugimoto, H
    Mammoto, T
    Charytan, D
    Strutz, F
    Kalluri, R
    [J]. NATURE MEDICINE, 2003, 9 (07) : 964 - 968
  • [57] ZHANG G, 2004, J AM SOC NEPHROL, V15, pA36
  • [58] Urokinase receptor deficiency accelerates renal fibrosis in obstructive nephropathy
    Zhang, GQ
    Kim, H
    Cai, XH
    López-Guisa, JM
    Alpers, CE
    Liu, YH
    Carmeliet, P
    Eddy, AA
    [J]. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2003, 14 (05): : 1254 - 1271